相关实验视频

Updated: May 17, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在新辅助免疫治疗后肺癌复发

Hao Li¹, Fatemehsadat Pezeshkian², Yue Xie³

¹Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass; Department of Thoracic Surgery, Institution of Thoracic Oncology, Peking University People's Hospital, Beijing, China.

The Journal of thoracic and cardiovascular surgery

|May 6, 2025

概括

在新辅助免疫疗法 (Neo-IO) 后,残留可活性瘤百分比 (%RVT) 是肺癌复发的关键预测因素. 5%和40%的最佳切断率%RVT识别高风险患者,指导治疗决策.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
胸部外科手术胸部外科手术

背景情况:

新辅助免疫疗法 (Neo-IO) 越来越多地用于切除的肺癌.
在Neo-IO和手术后预测复发风险对于患者管理至关重要.
剩余可活性瘤百分比 (%RVT) 是一个潜在的预后标记.

研究的目的:

评估可切除肺癌的Neo-IO后的复发风险和模式.
作为预后指标,确定%RVT的最佳切断值.

主要方法:

对94名可切除非小细胞肺癌患者的回顾性分析,这些患者接受了Neo-IO.治疗.
使用免疫相关的病理反应标准,在手术样本中量化%RVT.
使用Rhier函数来确定最佳的%RVT切断值以实现无复发生存 (RFS).

主要成果:

最佳的RVT截止率分别为5%和40%.
较高的RVT% (≥40%) 与明显更糟糕的RFS相关 (P=.006).
%RVT是RFS的一个独立风险因素 (HR,3.96;P=.015).
中原淋巴结的复发率随着晚期的ypN阶段 (ypN2: 25.0%) 增加.

结论:

%RVT是Neo-IO和切除后肺癌复发的独立预测指标.
5%和40%的切割率%RVT分层复发风险.
考虑对ypN2患者进行术后放射治疗,因为LN中枢线复发率高.

关键词:

化学免疫疗法化学免疫疗法肺癌是一种肺癌.新辅助免疫疗法新辅助免疫疗法复发性复发性复发性剩余的可活性瘤.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.